리포신LPCN 주가

♻️ 재탕[8-K] 중대 사건 — 8-K

Lipocine To Announce Phase 3 Data For LPCN 1154 Treatment For Postpartum Depression On May 26

Oral Presentation detailsTitle:Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154Presenter:Benjamin Bruno, PhD, Vice

♻️ 재탕[8-K] 중대 사건 — 8-K

♻️ 재탕[8-K] 중대 사건 — 8-K

♻️ 재탕[SCHEDULE 13G/A] SCHEDULE 13G/A

[SCHEDULE 13G] SCHEDULE 13G

Lipocine : Announces Financial Results for the First Quarter Ended March 31, 2026

SALT LAKE CITY, May 7, 2026 /PRNewswire / -- Lipocine Inc. , a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today...

♻️ 재탕CORRECTION: Lipocine Q1 EPS $(0.54) Misses $(0.48) Estimate, Sales $119.397K Miss $162.500K Estimate

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 12.5 percent. This is a 54.29 percent decrease over losses of $(0.35) per share from the

Lipocine Q1 EPS $(0.54) Misses $(0.48) Estimate, Sales $119.397M Beat $162.500K Estimate

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 12.5 percent. This is a 54.29 percent decrease over losses of $(0.35) per share from the

Lipocine: Q1 Earnings Snapshot

SALT LAKE CITY — SALT LAKE CITY — Lipocine Inc. on Thursday reported a loss of $3.7 million in its first quarter. The Salt Lake City-based company said it had a loss of 54 cents per share. ...